Evidence map›Paper›PMID 29702659›Full record

ArticlePloS one2018

Provider perspectives on PrEP for adolescent girls and young women in Tanzania: The role of provider biases and quality of care.

Nanlesta Pilgrim, Nrupa Jani, Sanyukta Mathur, Catherine Kahabuka, Vaibhav Saria, Neema Makyao, Lou Apicella, Julie Pulerwitz

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06133686 (Implementing Oral), which is not on this map. Cited by 60 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06133686 phase3not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa: a Phase 3b, Open-label, Hybrid Type 2 Implementation and Effectiveness Trial

TypeinterventionalSponsorMRC/UVRI and LSHTM Uganda Research UnitRan2024 to 2027Enrolled400ConditionsHIVArmsTenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA), Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC)
3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. "Journal of the International Association of Providers of AIDS Care
    Trial
  4. SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Nanlesta PilgrimPopulation Council, Washington, DC, United States of America.
Nrupa JaniPopulation Council, Washington, DC, United States of America.
Sanyukta MathurPopulation Council, Washington, DC, United States of America.ORCID 0000-0003-1645-6734
Catherine KahabukaCSK Research Solutions, Dar es Salaam, Tanzania.
Vaibhav SariaPopulation Council, Washington, DC, United States of America.
Neema MakyaoNational AIDS Control Programme, Dar es Salaam, Tanzania.
Lou ApicellaPopulation Council, Washington, DC, United States of America.
Julie PulerwitzPopulation Council, Washington, DC, United States of America.
Population Council · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral pre-exposure prophylaxis (PrEP) has the potential to reduce HIV acquisition among adolescent girls and young women (AGYW) in sub-Saharan Africa. However, health care providers' (HCPs) perspectives and interactions with potential clients can substantially influence effective provision of quality health services. We examine if HCPs' knowledge, attitude, and skills, as well as their perceptions of facility readiness to provide PrEP are associated with their willingness to provide PrEP to AGYW at high risk of HIV in Tanzania.

methodsA self-administered questionnaire was given to 316 HCPs from 74 clinics in two districts and 24 HCPs participated in follow-up in-depth interviews (IDIs). We conducted bivariate and multivariable Poisson regression to assess factors associated with willingness to provide PrEP to AGYW. Thematic content analysis was used to analyze the IDIs, which expanded upon the quantitative results.

resultsFew HCPs (3.5%) had prior PrEP knowledge, but once informed, 61.1% were willing to prescribe PrEP to AGYW. Higher negative attitudes toward adolescent sexuality and greater concerns about behavioral disinhibition due to PrEP use were associated with lower willingness to prescribe PrEP. Qualitatively, HCPs acknowledged that biases, rooted in cultural norms, often result in stigmatizing and discriminatory care toward AGYW, a potential barrier for PrEP provision. However, better training to provide HIV services was associated with greater willingness to prescribe PrEP. Conversely, HCPs feared the potential negative impact of PrEP on the provision of existing HIV services (e.g., overburdened staff), and suggested the integration of PrEP into non-HIV services and the use of paramedical professionals to facilitate PrEP provision.

conclusionsPreparing for PrEP introduction requires more than solely training HCPs on the clinical aspects of providing PrEP. It requires a two-pronged strategy: addressing HCPs' biases regarding sexual health services to AGYW; and preparing the health system infrastructure for the introduction of PrEP.

Indexed as

Attitude of Health PersonnelPre-Exposure ProphylaxisAdolescentAdultAnti-HIV AgentsFemaleHealth Knowledge, Attitudes, PracticeHealth PersonnelHIV InfectionsHumansMaleMiddle AgedMultivariate AnalysisOutcome Assessment, Health CarePatient-Centered CarePoisson DistributionAnti-HIV Agents

Identifiers

PMID29702659
PMCPMC5922529
OpenAlexW2801637111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.